UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

An expert consensus on the recommendations for the use of biomarkers in Fabry disease

Burlina, A; Brand, E; Hughes, D; Kantola, I; Krӓmer, J; Nowak, A; Tøndel, C; ... Spada, M; + view all (2023) An expert consensus on the recommendations for the use of biomarkers in Fabry disease. Molecular Genetics and Metabolism , 139 (2) , Article 107585. 10.1016/j.ymgme.2023.107585. Green open access

[thumbnail of 1-s2.0-S1096719223002159-main.pdf]
Preview
Text
1-s2.0-S1096719223002159-main.pdf - Published Version

Download (1MB) | Preview

Abstract

Fabry disease is an X-linked lysosomal storage disorder caused by the accumulation of glycosphingolipids in various tissues and body fluids, leading to progressive organ damage and life-threatening complications. Phenotypic classification is based on disease progression and severity and can be used to predict outcomes. Patients with a classic Fabry phenotype have little to no residual α-Gal A activity and have widespread organ involvement, whereas patients with a later-onset phenotype have residual α-Gal A activity and disease progression can be limited to a single organ, often the heart. Diagnosis and monitoring of patients with Fabry disease should therefore be individualized, and biomarkers are available to support with this. Disease-specific biomarkers are useful in the diagnosis of Fabry disease; non-disease-specific biomarkers may be useful to assess organ damage. For most biomarkers it can be challenging to prove they translate to differences in the risk of clinical events associated with Fabry disease. Therefore, careful monitoring of treatment outcomes and collection of prospective data in patients are needed. As we deepen our understanding of Fabry disease, it is important to regularly re-evaluate and appraise published evidence relating to biomarkers. In this article, we present the results of a literature review of evidence published between February 2017 and July 2020 on the impact of disease-specific treatment on biomarkers and provide an expert consensus on clinical recommendations for the use of those biomarkers.

Type: Article
Title: An expert consensus on the recommendations for the use of biomarkers in Fabry disease
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.ymgme.2023.107585
Publisher version: https://doi.org/10.1016/j.ymgme.2023.107585
Language: English
Additional information: © 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Keywords: Fabry disease, biomarkers, chaperone therapy, enzyme replacement therapy, therapeutic goal
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
URI: https://discovery.ucl.ac.uk/id/eprint/10171400
Downloads since deposit
54Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item